Last update 01 Nov 2024
Yingbairui (Hangzhou) Biomedical Co., Ltd.
Private Company|
2014|
Zhejiang Sheng, China
Last update 01 Nov 2024
Overview
Basic Info
Introduction Founded in 2014, Imbioray (Hangzhou) Biomedicine Co., Ltd. specializes in treatments for cancer and immune-related diseases. By 2016, the company shifted its focus towards the development of innovative, off-the-shelf CAR-NK cell therapies. |
Tags
Neoplasms
Hemic and Lymphatic Diseases
Immune System Diseases
CAR-NK
Immune cell therapy
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
一项评价IBR733细胞注射液治疗急性髓系白血病的安全性、耐受性及初步疗效的开放、多中心I期临床研究
[Translation] An open, multicenter phase I clinical study to evaluate the safety, tolerability and preliminary efficacy of IBR733 cell injection in the treatment of acute myeloid leukemia
An Open-label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBR733 Cell Injection in Acute Myeloid Leukemia
A Phase I Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBR854 Cell Injection in Patients With Unresectable Locally Advanced Or Metastatic Solid Tumors
100 Clinical Results associated with Yingbairui (Hangzhou) Biomedical Co., Ltd.
Login to view more data
Login to view more data
100 Deals associated with Yingbairui (Hangzhou) Biomedical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Yingbairui (Hangzhou) Biomedical Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 26 Nov 2024
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
4
1
Other
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free